Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq and scRNA-seq gene expression of breast tumors with mutant p53 or mutant p53 deleted

ABSTRACT: RNA-seq and scRNA-seq gene expression of breast tumors with mutant p53 or mutant p53 deleted

PROVIDER: PRJNA882488 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

scRNA gene expression of breast tumors with mutant p53 or mutant p53 deleted [scRNA-seq]

Project description:scRNA gene expression of breast tumors with mutant p53 or mutant p53 deleted [scRNA-seq]

| PRJNA882491 | ENA

Gene expression of breast tumors with mutant p53 or mutant p53 deleted [RNA-seq]

Project description:Gene expression of breast tumors with mutant p53 or mutant p53 deleted [RNA-seq]

| PRJNA882490 | ENA

Gene expression of breast tumors with mutant p53 or mutant p53 deleted [RNA-seq]

Project description:We conducted gene expression analysis from total tumor treated with AAV-Control or AAV-mut-p53 deleted.

2023-08-18 | GSE213822 | GEO

scRNA gene expression of breast tumors with mutant p53 or mutant p53 deleted [scRNA-seq]

Project description:We conducted gene expression analysis from total tumor treated with AAV-Control or AAV-mut-p53 deleted in an acute setting.

2024-01-01 | GSE213823 | GEO

Exosomes of p53 mutant H1299 cells

Project description:Proteome of exosomes purified from H1299-p53R273H (mutant) and H1299-p53-/- cells, which found the levels of Podocalyxin altered in p53-mutant cells.

2018-12-04 | PXD011241 | Pride

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

Project description:This research study is studying a drug as a possible treatment for p53 mutant metastatic colorectal cancer. The drug involved in this study is: -Lamivudine

| 2243737 | ecrin-mdr-crc

LINC01021 attenuates expression and affects alternative splicing of a subset of p53-regulated genes

Project description:Loss of the p53-inducible LINC01021 in p53-proficient CRC cell lines results in increased sensitivity to DNA-damaging chemotherapeutics. Here, we comprehensively analyzed how LINC01021 affects the p53-induced transcriptional program. Using a CRISPR/Cas9-approach we deleted the p53 binding site in the LINC01021 promoter of SW480 colorectal cancer cells and subjected them to RNA-Seq analysis after activation of ectopic p53. RNA affinity purification followed by mass spectrometry was used identify proteins associated with LINC01021.

2024-05-10 | PXD050892 | Pride

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

Project description:exosomes isolated from: HT29+control shRNA; HT29+p53 shRNA; HCT116 WT p53; HCT116 mutant p53; HCT116 null p53; media used as negative control

2018-02-09 | MSV000082047 | MassIVE

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation [ChIP-seq]

Project description:Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation [ChIP-seq]

| PRJNA528475 | ENA

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation [RNA-seq]

Project description:Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation [RNA-seq]

| PRJNA529802 | ENA